MDS Receives U.S. Federal Trade Commission Provisional Regulatory Approval for Sale of MDS Analytical Technologies
January 27 2010 - 2:59PM
PR Newswire (US)
Approval a Significant Milestone Toward Close of Transaction
TORONTO, Jan. 27 /PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS;
NYSE: MDZ), a leading provider of products and services to the
global life sciences markets, today announced that the Company has
received provisional anti-trust approval from the United States
Federal Trade Commission (FTC) for the proposed sale of MDS
Analytical Technologies to Danaher Corporation (NYSE: DHR). All
other requisite regulatory approvals required for the completion of
the acquisition have now been received. The sale of MDS Analytical
Technologies to Danaher, which was announced on September 2, 2009,
is expected to close before the end of the first calendar quarter
of 2010, subject to the satisfaction of conditions to closing.
About MDS MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences
company that provides market-leading products and services that
customers need for the development of drugs and the diagnosis and
treatment of disease. MDS Inc. is a leading global provider of
innovative technologies for use in medical imaging and
radiotherapeutics, sterilization, pharmaceutical contract research,
and analytical instruments. MDS has more than 3,500 highly skilled
people in 13 countries. Find out more at http://www.mdsinc.com/ or
by calling 1-888-MDS-7222, 24 hours a day. DATASOURCE: MDS Inc.
CONTACT: MEDIA: Janet Ko, (905) 267-4226, ; INVESTORS: Catherine
Love, (905) 267-4230,
Copyright